Press Release Oct 07 2024

Wockhardt Limited has informed the Exchange regarding a press release dated October 07, 2024, titled "Wockhardt's another breakthrough antibiotic: once-a-day β-lactam enhancer, WCK 6777 (Ertapenem/Zidebactam) with unique out-patient treatment advantage granted Fast Track designation by US FDA and successfully completes Phase I study conducted by National Institutes of Health, US".

View Attachment